Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 216

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 216
---
21, 2025, we owned approximately 43 patents and pending patent applications in the United States and foreign jurisdictions
relating to LB-102, including five issued U.S. patents and 11 issued foreign patents, seven pending U.S. patent applications, 19 pending foreign applications, and one pending patent cooperation treaty, or PCT,
application.

152

We own all of the following patents and pending patent applications directed to LB-102,which are summarized below:

| Indication(s)                            |     | Subject Matter                                |     |  Projected 
 Expiration 
      Date* |     | Issued or Pending Patent Applications/                                                                                                                                                                                                  
 Jurisdiction                                                                                                                                                                                                                            |
| Schizophrenia and other mental illnesses |     | Composition of Matter and method of treatment |     |       2037 |     | Respectively, one patent issued in each of the following: Australia, EPO, Indonesia, Japan, Republic of Korea, Malaysia, and Singapore, two patents issued in China and Hong Kong, and five patents issued in the United States; one    
 patent application pending in each of the following: Australia, Brazil, Malaysia, New Zealand, Singapore, and the United States                                                                                                         |
|                                          |     | Method of Treatment                           |     |       2042 |     | Respectively, one patent application pending in each of the following: Australia, Brazil, Canada, China, EPO, Japan, Republic of Korea, Malaysia, New Zealand, Singapore, and the United States; and two patent applications pending in 
 Hong Kong                                                                                                                                                                                                                               |
|                                          |     | Method of Treatment (Poor Cognition)          |     |       2044 |     | One PCT application pending; and one application pending in Taiwan.                                                                                                                                                                     |
|                                          |     | Method of Treatment                           |     |       2046 |     | Five provisional applications pending in the United States.                                                                                                                                                                             |

| * | Projected expiration dates are based on issued patents or patents that may be issued from pending patent                                                                                        
 applications, and do not take into account possible patent term adjustments, extensions, or terminal disclaimers and assumes payment of all appropriate maintenance, renewal, and annuity fees. |

With respect to LB-102,our U.S. and foreign patents and pending patent applications cover claims directed to composition of matter, and method of treating schizophrenia and other mental illnesses such as depression, bipolar disorder, Tourette’s syndrome, schizoaffective disorder, Parkinson’s psychosis, Alzheimer’s psychosis, oppositional defiant